Eli Lilly Financial Statements
NYSE: LLYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Eli Lilly revenue and earnings
In fiscal 2025, Eli Lilly generated $65.18 billion in revenue, up 44.7% from fiscal 2024, its 8th consecutive year of revenue growth. Net income was $20.64 billion (+94.9% year over year), for a net margin of 31.7% versus a median of 21.9% in the prior 5 years. Gross margin was 83.0% (up from 81.3%).
Diluted earnings per share came in at $22.95, up from $11.71. Over the last 5 fiscal years, LLY's revenue has grown at a 21.6% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Eli Lilly income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.18B | 45.04B | 34.12B | 28.54B | 28.32B | 24.54B | 22.32B | 21.49B | 19.97B | 21.22B |
| Revenue growth (YoY) | +44.70% | +32.00% | +19.56% | +0.79% | +15.40% | +9.95% | +3.84% | +7.61% | -5.88% | +6.33% |
| Cost of Revenue | 11.05B | 8.42B | 7.08B | 6.63B | 7.31B | 5.48B | 4.72B | 4.68B | 4.45B | 5.71B |
| Gross Profit | 54.13B | 36.63B | 27.04B | 21.91B | 21.01B | 19.06B | 17.60B | 16.81B | 15.53B | 15.51B |
| Research & Development | 13.34B | 10.99B | 9.31B | 7.19B | 6.93B | 5.98B | 5.59B | 5.05B | 5.10B | 5.31B |
| Selling, General & Admin | 11.09B | 8.59B | 7.40B | 6.44B | 6.43B | 6.12B | 6.21B | 5.98B | 5.98B | 6.53B |
| Interest Expense | 895.00M | 781.00M | 485.90M | 331.60M | 339.80M | 359.60M | 400.60M | 242.50M | 225.00M | 185.20M |
| Other Income (Expense) | -571.00M | -219.00M | 97.00M | -320.90M | -201.60M | 1.17B | 291.60M | 145.60M | 301.50M | 112.80M |
| Pretax Income | 25.73B | 12.68B | 6.55B | 6.81B | 6.16B | 7.23B | 5.27B | 3.68B | 2.30B | 3.37B |
| Income Tax | 5.09B | 2.09B | 1.31B | 561.60M | 573.80M | 1.04B | 628.00M | 529.50M | 2.39B | 636.40M |
| Net Income | 20.64B | 10.59B | 5.24B | 6.24B | 5.58B | 6.19B | 8.32B | 3.23B | -204.10M | 2.74B |
| Net Income growth (YoY) | +94.90% | +102.10% | -16.09% | +11.88% | -9.88% | -25.54% | +157.38% | — | -107.46% | +13.67% |
| EPS (Basic) | 23.00 | 11.76 | 5.82 | 6.93 | 6.15 | 6.82 | 8.93 | 3.14 | -0.19 | 2.59 |
| EPS (Diluted) | 22.95 | 11.71 | 5.80 | 6.90 | 6.12 | 6.79 | 8.89 | 3.13 | -0.19 | 2.58 |
| Shares Outstanding (Basic) | 897.30M | 900.60M | 900.20M | 901.74M | 906.96M | 907.63M | 931.06M | 1.03B | 1.05B | 1.06B |
| Shares Outstanding (Diluted) | 899.30M | 904.10M | 903.30M | 904.62M | 911.68M | 912.50M | 935.68M | 1.03B | 1.05B | 1.06B |
| Gross Margin | 83.04% | 81.31% | 79.25% | 76.77% | 74.18% | 77.66% | 78.85% | 78.22% | 77.73% | 73.09% |
| Net Margin | 31.67% | 23.51% | 15.36% | 21.88% | 19.71% | 25.24% | 37.27% | 15.04% | -102.00% | 12.90% |
This table shows 10 annual periods of Eli Lilly's income statement, from FY 2025 back to FY 2016, across 16 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow LLY's reporting calendar. What is a income statement?